openPR Logo
Press release

Investigation announced for Investors who lost money with shares of AlloVir, Inc. (NASDAQ: ALVR) over potential Wrongdoing

An investigation on behalf of current long term investors in AlloVir, Inc. (NASDAQ: ALVR) shares.

An investigation on behalf of current long term investors in AlloVir, Inc. (NASDAQ: ALVR) shares.

An investigation was announced for long-term investors in shares of AlloVir, Inc. (NASDAQ: ALVR) concerning potential breaches of fiduciary duties by certain directors and officers of AlloVir, Inc.

Investors who are current long term investors in AlloVir, Inc. (NASDAQ: ALVR) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

The investigation by a law firm for current long term investors in NASDAQ: ALVR stocks follows a lawsuit filed against AlloVir, Inc. over alleged securities laws violations. The investigation on behalf of current long term investors in NASDAQ: ALVR stocks, concerns whether certain AlloVir, Inc. directors are liable in connection with the allegations made in that lawsuit.

According to that complaint filed in the U.S. District Court for the District of Massachusetts the plaintiff alleges that, the defendants made false and/or misleading statements and/or failed to disclose that the posoleucel Phase 3 Studies were unlikely to meet their primary endpoints, that as a result, it was likely that the Company would ultimately discontinue the posoleucel Phase 3 studies, that accordingly, AlloVir overstated the efficacy and clinical and/or commercial prospects of posoleucel, and that as a result, the Company's public statements were materially false and misleading at all relevant times.

On June 17, 2024, an mended Complaint was filed.

Those who purchased shares of AlloVir, Inc. (NASDAQ: ALVR) have certain options and should contact the Shareholders Foundation.

Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Investigation announced for Investors who lost money with shares of AlloVir, Inc. (NASDAQ: ALVR) over potential Wrongdoing here

News-ID: 3635409 • Views:

More Releases from Shareholders Foundation, Inc.

Gauzy Ltd. (NASDAQ: GAUZ) Investor Alert: Lawsuit alleges False and Misleading Statements
Gauzy Ltd. (NASDAQ: GAUZ) Investor Alert: Lawsuit alleges False and Misleading S …
An investor, who purchased shares of Gauzy Ltd. (NASDAQ: GAUZ), filed a lawsuit in the U.S. District Court for the Southern District of New York over alleged violations of Federal Securities Laws by Gauzy Ltd. in connection with certain allegedly false and misleading statements. Investors who purchased shares of Gauzy Ltd. (NASDAQ: GAUZ) have certain options and for certain investors are short and strict deadlines running. Deadline: February 6, 2026. NASDAQ:
Lawsuit ALERT: Investors with losses in Blue Owl Capital Inc. (NYSE: OWL) should contact the Shareholders Foundation
Lawsuit ALERT: Investors with losses in Blue Owl Capital Inc. (NYSE: OWL) should …
An investor, who purchased shares of Blue Owl Capital Inc. (NYSE: OWL), filed a lawsuit in the U.S. District Court for the Southern District of New York over alleged violations of Federal Securities Laws by Blue Owl Capital Inc. Investors who purchased shares of Blue Owl Capital Inc. (NYSE: OWL) have certain options and for certain investors are short and strict deadlines running. Deadline: February 2, 2026. NYSE: OWL investors should
Lawsuit NOTICE: Investors in Bitdeer Technologies Group (NASDAQ: BTDR) should contact the Shareholders Foundation
Lawsuit NOTICE: Investors in Bitdeer Technologies Group (NASDAQ: BTDR) should co …
An investor, who purchased shares of Bitdeer Technologies Group (NASDAQ: BTDR), filed a lawsuit over alleged violations of Federal Securities Laws by Bitdeer Technologies Group in connection with certain allegedly false and misleading statements. Investors who purchased shares of Bitdeer Technologies Group (NASDAQ: BTDR) have certain options and for certain investors are short and strict deadlines running. Deadline: February 02, 2026. NASDAQ: BTDR investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com
Lawsuit Alert: Investors who lost money with shares of DeFi Technologies Inc. (NASDAQ: DEFT) should contact the Shareholders Foundation
Lawsuit Alert: Investors who lost money with shares of DeFi Technologies Inc. (N …
An investor, who purchased shares of DeFi Technologies Inc. (NASDAQ: DEFT), filed a lawsuit over alleged violations of Federal Securities Laws by DeFi Technologies Inc. in connection with certain allegedly false and misleading statements. Investors who purchased shares of DeFi Technologies Inc. (NASDAQ: DEFT) have certain options and for certain investors are short and strict deadlines running. Deadline: January 30, 2026. NASDAQ: DEFT investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com

All 5 Releases


More Releases for AlloVir

Parainfluenza Virus Infection Market: Insights on Epidemiology, Treatments, and …
The Parainfluenza Virus Infection Market is projected to witness consistent growth throughout the forecast period (2024-2034). The Parainfluenza Virus Infection Market Size in the 7MM is expected to increase, driven by increasing Incident population. Emerging therapies for Parainfluenza virus infection, including DAS181, ALVR106, and others, are expected to drive growth in the Parainfluenza virus infection market in the coming years. DelveInsight has released a new report titled "Parainfluenza Virus Infection - Market
Parainfluenza Virus Infection Market to Expand Significantly by 2034, States Del …
DelveInsight's "Parainfluenza Virus Infection Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Parainfluenza Virus Infection, historical and forecasted epidemiology as well as the Parainfluenza Virus Infection market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan. The latest healthcare forecast report provides an in-depth analysis of Parainfluenza Virus Infection, offering comprehensive insights into the Parainfluenza Virus Infection revenue trends,
Parainfluenza virus infection Market: Epidemiology, Therapies, Companies, DelveI …
Parainfluenza virus infection therapies, such as DAS181, ALVR106, and others, are expected to boost the Parainfluenza virus infection Market in the upcoming years. DelveInsight has launched a new report on "Parainfluenza virus infection - Market Insights, Epidemiology, and Market Forecast-2034" that delivers an in-depth understanding of the Parainfluenza virus infection, historical and forecasted epidemiology as well as the Parainfluenza virus infection market trends in the United States, EU5 (Germany, Spain, Italy,
Parainfluenza Virus Infection Market to Expand Significantly by 2034, States Del …
The Key Parainfluenza Virus Infection Companies in the market include - Ansun Biopharma, AlloVir, MedImmune LLC, and others. DelveInsight's "Parainfluenza Virus Infection Market Insights, Epidemiology, and Market Forecast-2034 report offers an in-depth understanding of the Parainfluenza Virus Infection, historical and forecasted epidemiology as well as the Parainfluenza Virus Infection market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan. The latest healthcare forecast report provides an
Adenovirus Infections Market to Rise by 2032 | Tianjin CanSino Biotechnology, Ku …
DelveInsight's "Adenovirus Infections Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of Adenovirus Infections, historical and forecasted epidemiology as well as the Adenovirus Infections market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan. The Adenovirus Infections market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Adenovirus Infections market size
Influenza Pipeline Drugs 2024 | Moderna, SAB Biotherapeutics, ENA Respiratory Pt …
DelveInsight's, "Influenza Pipeline Insight 2024" report provides comprehensive insights about 120+ companies and 120+ pipeline drugs in Influenza pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Discover the latest drugs and treatment options in the Influenza Pipeline. Dive into